Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, FTIH Study to Investigate the Safety, Tolerability, PK and PD of ECC4703 in Healthy Volunteers and Participants With Treatment-Unnecessary LDL-C Under 160 mg/dL

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, FTIH Study to Investigate the Safety, Tolerability, PK and PD of ECC4703 in Healthy Volunteers and Participants With Treatment-Unnecessary LDL-C Under 160 mg/dL

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ECC-4703 (Primary)
  • Indications Dyslipidaemias; Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Sponsors Eccogene

    • Most Recent Events

    • 15 Nov 2024 According to an Eccogene media release, data from this trial will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting.
    • 15 Nov 2024 Results presented in an Eccogene Media Release.
    • 11 Jun 2023 According to an Eccogene media release, the company announced a CNY 180 million Series B financing. The proceeds from the financing will be used to support the clinical development including this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top